Longer Duration Versus Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Short Title: NRG-BN013

Enrollment Status: Recruiting

NCT #: NCT06500455

Specialty Area: Oncology

Condition Studied: Brain Metastases

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out if giving fractionated stereotactic radiosurgery (FSRS) over three sessions is more effective than the usual single-session stereotactic radiosurgery (SRS) in treating brain metastases and preventing tumor regrowth.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with stage IV cancer that has spread to the brain (metastatic)
Eligible for stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (FSRS)
Must have at least 1 and up to 8 total intact brain metastases

What's Involved

Participation in the study will include:

Radiation therapy using either stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (FSRS)
CT/MRI scans to monitor tumor response
Questionnaires

Principal Investigator

Mauricio Perez Davila, MD

General Neurology

A Member of

(775) 982–5000

Renown Institute for Neurosciences

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06500455

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews